European ADRs Move Higher Trading

European ADRs Move Higher Trading

American depositary receipts of European stocks were trading 0.12% higher at 133.32 on the Bank of New York Mellon Europe ADR Index on Friday. In continental Europe, the gainers were led by biopharmaceutical company Ascendis Pharma (ASND), which surged 7.7%, followed by cell therapy company TiGenix (TIG), which rose 3.7%. ASML (ASML), a manufacturer of chip-making equipment, and biopharmaceutical company DBV Technologies (DBVT) increased 2.7% and 2.3% each. The decliners […]

Read More ˃
Aurinia Pharmaceuticals Reports New Phase IIb Data

Aurinia Pharmaceuticals Reports New Phase IIb Data

Shares of Aurinia Pharmaceuticals Inc. were up over 5% in pre-market trading after it reported new remission data from its phase IIB AURA-LV (AURA) study in lupus nephritis (LN) The company said the data demonstrated that over the course of the 48-week trial, patients on voclosporin stayed in remission approximately twice as long as those in the control group. It said the differences were statistically significant versus the control arm, […]

Read More ˃
Bond Prices Pare Losses

Bond Prices Pare Losses

U.S. Treasury prices bounced after a successful three-year note auction Monday, after having stalled into a range earlier in front of a batch of auctions, coming key data and the expected rate hike out of the Federal Open Market Committee (FOMC) meeting Wednesday. The market will need to digest the1 p.m. ET $20 billion reopened 10-year notes and $12 billion reopened 30-year bonds Tuesday (versus a usual three day schedule) […]

Read More ˃
Osisko Gold Royalties Buys Orion Mine Finance Portfolio

Osisko Gold Royalties Buys Orion Mine Finance Portfolio

Osisko Gold Royalties said Monday it has reached a deal with Orion Mine Finance Group to acquire a precious metals portfolio consisting of 74 royalties, streams and precious metal offtakes for roughly C$1.13 billion ($835 million). The acquisition is expected to be immediately accretive to cash flow, Osisko said. The transaction gives the company forecasted production of over 100,000 gold equivalent ounces, or GEOs, in 2018 growing to over 140,000 […]

Read More ˃
Abeona Therapeutics Gets Rare Pediatric Disease Designation

Abeona Therapeutics Gets Rare Pediatric Disease Designation

Abeona Therapeutics said early Tuesday that the US Food and Drug Administration has grated a rare pediatric disease designation to its EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa, including recessive dystrophic epidermolysis bullosa, which are life-threatening genetic skin disorders characterized by skin blisters and erosions that cover the body. With this designation, the FDA may give the company a pediatric priority review voucher if the drug is […]

Read More ˃